Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1464Pancreatic Neoplasms 833Stomach Neoplasms 693Carcinoma, Hepatocellular 648Carcinoma, Non-Small-Cell Lung 543Neoplasms 459Breast Neoplasms 369Ovarian Neoplasms 338Neoplasm Metastasis 337Colonic Neoplasms 332Esophageal Neoplasms 297Liver Neoplasms 266Melanoma 255Lung Neoplasms 246Squamous Cell Carcinoma of Head and Neck 210Cholangiocarcinoma 181Carcinoma, Renal Cell 181Prostatic Neoplasms 175Head and Neck Neoplasms 172Triple Negative Breast Neoplasms 163Rectal Neoplasms 160Endometrial Neoplasms 160Uterine Cervical Neoplasms 155Gastrointestinal Neoplasms 142Urinary Bladder Neoplasms 139Biliary Tract Neoplasms 136Gastrointestinal Stromal Tumors 108Sarcoma 105Esophageal Squamous Cell Carcinoma 102Small Cell Lung Carcinoma 95

Interventions

camrelizumab 1apatinib 1Folfox protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Primary Liver Cancer × Gastrointestinal × Clear all
NCT03092895 2026-01-29

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
157 enrolled 17 charts
Gastrointestinal

Advanced Primary Liver Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡